More recently, using the B16 melanoma model, VEGF-C-induced CCL21/CCR7-mediated lymphangiogenesis that promoted the entry of naïve T cells into melanomas and thereby, enhanced the activity of immunotherapy [232]. This evidence concerns the gene CCR7 and melanoma.